Monte Rosa Therapeutics swings to Q3 net income of $3.06 million from year-earlier loss
GLUE•GLUE•GLUE•GLUE•Monte Rosa Therapeutics reported third-quarter 2026 net income of $3.06 million, compared with a year-earlier net loss of $27.08 million. Collaboration revenue was $54.37 million, including a $50 million milestone, and cash and marketable securities totaled $582.6 million.
Monte Rosa Therapeutics swung to third-quarter 2026 net income of $3.06 million from a net loss of $27.08 million a year earlier. Collaboration revenue rose to $54.37 million, primarily driven by a $50 million milestone for initiation of Novartis’s Sjögren’s disease study. Cash, cash equivalents, restricted cash and marketable securities totaled $582.6 million at September 30, which the company expects to support operations into 2029.
The company expects to begin the Phase 2 gout study of MRT-8102 in the fourth quarter of 2026, with initial data anticipated in the second half of 2027. Dosing in the Phase 2 MODeFIRe-1 prostate cancer study began in August, and a clinical data update is expected in 2027.
